Evommune financials
$8.35−0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$34.9M | -$24.0M | -$29.7M |
| Net income | -$32.2M | -$21.7M | -$28.3M |
| Net margin | — | — | — |
| Diluted EPS | $-0.89 | $-0.64 | $-1.42 |
| EBITDA | -$34.3M | -$23.6M | -$29.4M |
| Operating cash flow | -$20.3M | -$27.5M | -$16.7M |
| Free cash flow | -$20.5M | -$27.6M | -$16.8M |
| Diluted shares | 36.1M | 33.7M | 19.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $60.0M | $48.3M | $44.1M |
| Short-term investments | $140.8M | $163.1M | $105.1M |
| Total debt | $434.0K | $529.0K | $181.0K |
| Total assets | $301.9M | $322.5M | $224.9M |
| Total liabilities | $24.4M | $17.9M | $19.4M |
| Shareholders' equity | $277.6M | $304.6M | $205.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology